BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 96 filers reported holding BIOXCEL THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 1.24 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $33,851 | -72.4% | 13,380 | -27.5% | 0.00% | – |
Q2 2023 | $122,871 | -33.4% | 18,449 | +86.7% | 0.00% | – |
Q1 2023 | $184,398 | -11.3% | 9,882 | +2.1% | 0.00% | – |
Q4 2022 | $207,883 | +94.3% | 9,678 | +7.5% | 0.00% | – |
Q3 2022 | $107,000 | -6.1% | 9,000 | +3.5% | 0.00% | – |
Q2 2022 | $114,000 | -35.2% | 8,699 | +3.6% | 0.00% | – |
Q1 2022 | $176,000 | +4.1% | 8,393 | +1.0% | 0.00% | – |
Q4 2021 | $169,000 | -32.9% | 8,314 | 0.0% | 0.00% | – |
Q3 2021 | $252,000 | +98.4% | 8,314 | +91.0% | 0.00% | – |
Q2 2021 | $127,000 | -29.1% | 4,352 | +4.8% | 0.00% | – |
Q1 2021 | $179,000 | -8.2% | 4,152 | -1.7% | 0.00% | – |
Q4 2020 | $195,000 | +143.8% | 4,224 | +129.9% | 0.00% | – |
Q3 2020 | $80,000 | -31.0% | 1,837 | -15.7% | 0.00% | – |
Q2 2020 | $116,000 | +383.3% | 2,179 | +105.2% | 0.00% | – |
Q1 2020 | $24,000 | +33.3% | 1,062 | -13.7% | 0.00% | – |
Q4 2019 | $18,000 | +157.1% | 1,230 | +22.4% | 0.00% | – |
Q3 2019 | $7,000 | -36.4% | 1,005 | 0.0% | 0.00% | – |
Q2 2019 | $11,000 | – | 1,005 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
LUMINUS MANAGEMENT LLC | 157,099 | $4,565,000 | 0.66% |
ACT CAPITAL MANAGEMENT, LLC | 42,000 | $1,221,000 | 0.63% |
Knoll Capital Management, LLC | 20,000 | $581,000 | 0.30% |
Artemis Investment Management LLP | 1,193,290 | $34,664,000 | 0.30% |
Ghisallo Capital Management LLC | 225,000 | $6,539,000 | 0.25% |
Monashee Investment Management LLC | 60,000 | $1,744,000 | 0.21% |
AlphaCentric Advisors LLC | 25,000 | $727,000 | 0.20% |
CAAS CAPITAL MANAGEMENT LP | 232,285 | $6,750,000 | 0.11% |
AllSquare Wealth Management LLC | 5,402 | $157,000 | 0.09% |
CNA FINANCIAL CORP | 9,479 | $275,000 | 0.08% |